Review Article ISSN 2639-9326

Diabetes & its Complications

Thyroid Gland Pathophysiology, Autoimmune Disorders, and Contemporary Therapeutic Strategies: A Comprehensive Review

Anvi Rana*

Lovely Professional University, India.

***Correspondence:**
Anvi Rana, Lovely Professional University, India.

Received: 10 Apr 2026; **Accepted:** 09 May 2026; **Published:** 19 May 2026

Citation: Anvi Rana. Thyroid Gland Pathophysiology, Autoimmune Disorders, and Contemporary Therapeutic Strategies: A Comprehensive Review. Diabetes Complications. 2026; 10(2); 1-4.

ABSTRACT

The thyroid gland is a critical endocrine organ whose hormones govern metabolic homeostasis, cardiovascular function, neurological development, and systemic physiological balance. Thyroid disorders encompass a broad spectrum of conditions including autoimmune diseases such as Hashimoto's thyroiditis and Graves' disease, structural abnormalities such as nodules and goiter, and malignancies ranging from well-differentiated papillary carcinoma to aggressive anaplastic cancer. These disorders represent a significant global health burden, with hypothyroidism and hyperthyroidism affecting millions of individuals worldwide. This review synthesizes current evidence on the molecular mechanisms of thyroid hormone biosynthesis and action, the immunopathogenesis of autoimmune thyroid diseases, the epidemiology and clinical management of thyroid dysfunction, recent advances in thyroid cancer diagnosis and targeted therapy, and the role of nutritional factors such as iodine and vitamin D in thyroid health. Emerging insights into genetic predisposition, thyroid ultrasound scoring systems, and personalized treatment approaches are also critically examined. This comprehensive review aims to provide a foundation for advanced research and improved clinical practice in thyroid endocrinology.

Keywords

Thyroid disorders, Hashimoto's thyroiditis, Graves' disease, Hypothyroidism, Thyroid cancer, Autoimmunity, Thyroid hormones, TSH, Levothyroxine.

Introduction

The thyroid gland, a butterfly-shaped organ situated anterior to the trachea in the neck, is among the most metabolically active endocrine structures in the human body. Through the synthesis and secretion of thyroxine (T4) and triiodothyronine (T3), it regulates basal metabolic rate, thermogenesis, cardiac output, and the development of the central nervous system [1]. The hypothalamic-pituitary-thyroid (HPT) axis precisely controls thyroid function; thyrotropin-releasing hormone (TRH) from the hypothalamus stimulates pituitary secretion of thyroid-stimulating hormone (TSH), which in turn drives thyroid hormone production [2].

Thyroid diseases are among the most prevalent endocrine conditions globally. According to population-based data from the National Health and Nutrition Examination Survey (NHANES III), approximately 4.6% of the United States population has hypothyroidism and 1.3% has hyperthyroidism [3]. Globally, iodine deficiency remains the leading preventable cause of thyroid dysfunction and intellectual disability [4]. Autoimmune thyroid diseases, particularly Hashimoto's thyroiditis and Graves' disease, represent leading causes of thyroid dysfunction in iodine-sufficient regions [5,6].

Given the heterogeneity of thyroid pathology and the growing importance of precision medicine, a comprehensive review of thyroid physiology, disease mechanisms, and current management strategies is warranted. This paper addresses these areas systematically, drawing from landmark clinical trials, meta-analyses, and current guidelines, with the aim of informing advanced research and clinical decision-making in thyroid endocrinology.

Thyroid Hormone Biosynthesis and Mechanism of Action

Biosynthesis and Regulation

Thyroid hormone biosynthesis is a multi-step process requiring iodine as an essential substrate. Dietary iodide is actively transported into thyroid follicular cells via the sodium-iodide symporter (NIS), oxidized by thyroid peroxidase (TPO), and organified onto tyrosine residues of thyroglobulin to form monoiodotyrosine (MIT) and diiodotyrosine (DIT). Coupling of these intermediates yields T4 and T3, which are stored in the colloid and subsequently released upon TSH stimulation [7]. This intricate biosynthetic pathway is tightly regulated by the HPT axis through negative feedback, wherein circulating T3 and T4 suppress TRH and TSH secretion [2].

Molecular Actions of Thyroid Hormones

T3, the biologically active form, exerts its effects primarily through nuclear thyroid hormone receptors (TRα and TRβ), which modulate gene transcription by binding to thyroid hormone response elements (TREs) in target gene promoters [1]. Non-genomic actions, mediated via membrane receptors and cytoplasmic signaling cascades, contribute to rapid cardiovascular and neurological responses [2]. Tissue-specific deiodinase enzymes (DIO1, DIO2, DIO3) regulate intracellular T3 availability, and polymorphisms in DIO2 have been associated with variations in psychological well-being and treatment response in hypothyroid patients [8].

Epidemiology of Thyroid Disorders

Thyroid disorders affect an estimated 750 million people globally, making them one of the most common endocrine diseases worldwide [9]. The prevalence varies considerably by geographic region, iodine intake, age, sex, and ethnicity. Women are disproportionately affected, with a female-to-male ratio of approximately 5-10:1 for autoimmune thyroid diseases [9]. Hypothyroidism, particularly subclinical hypothyroidism, is prevalent in older women and those with pre-existing autoimmune conditions [10].

Subclinical thyroid disease defined as an abnormal serum TSH level with normal thyroid hormone concentrations is highly prevalent and carries prognostic implications for cardiovascular morbidity, neuropsychiatric dysfunction, and progression to overt disease [11]. A systematic review by Cooper and Biondi highlighted the cardiovascular risks associated with both subclinical hypothyroidism and hyperthyroidism, underscoring the importance of early detection and management [11]. Population screening programs, particularly in high-risk groups such as pregnant women, the elderly, and those with family histories of thyroid disease, have been advocated [12].

Autoimmune Thyroid Diseases

Hashimoto's Thyroiditis

Hashimoto's thyroiditis (HT), also known as chronic lymphocytic thyroiditis, is the most common cause of hypothyroidism in iodine-sufficient populations [13]. It is characterized by lymphocytic infiltration of the thyroid parenchyma, progressive follicular destruction, and the presence of circulating autoantibodies against TPO (anti-TPO) and thyroglobulin (anti-Tg) [14]. The immunopathogenesis involves a breakdown of self-tolerance, with both CD4+ T helper cells and B cells contributing to thyrocyte apoptosis through cytotoxic mechanisms and antibody-dependent cellular cytotoxicity [13].

Genetic susceptibility to HT involves HLA class II alleles, particularly HLA-DR3 and HLA-DR5, as well as non-HLA genes including CTLA-4, PTPN22, and thyroglobulin gene variants [6]. Environmental triggers, including excess iodine intake, selenium deficiency, infections, and psychological stress, may precipitate disease onset in genetically susceptible individuals [14]. Treatment with levothyroxine (LT4) is indicated once overt hypothyroidism develops, with TSH normalization as the therapeutic target [15].

Graves' Disease

Graves' disease (GD) is the predominant cause of hyperthyroidism in developed countries, affecting approximately 0.5% of the population [16]. It is an organ-specific autoimmune condition in which stimulating autoantibodies against the TSH receptor (TRAb) activate thyroid hormone synthesis and secretion, leading to thyrotoxicosis [16]. Clinical manifestations include goiter, ophthalmopathy, dermopathy, and a constellation of hyperthyroid symptoms including palpitations, weight loss, heat intolerance, and anxiety [17].

Management options include antithyroid drugs (ATDs) such as methimazole and propylthiouracil, radioactive iodine (RAI) therapy, and thyroidectomy [18]. Long-term remission rates with ATDs are approximately 40-60%, and relapse predictors include goiter size, TRAb titers, and severity of thyrotoxicosis at presentation [17]. The 2016 American Thyroid Association guidelines recommend individualized treatment selection based on patient preference, disease severity, and comorbidities [17].

Thyroid Nodules and Thyroid Cancer

Evaluation of Thyroid Nodules

Thyroid nodules are exceedingly common, detected by ultrasonography in up to 68% of the general population [19,20]. While the majority are benign, approximately 5–15% harbor malignancy, necessitating systematic evaluation [21]. The American Thyroid Association's 2015 guidelines recommend risk stratification based on ultrasound characteristics including echogenicity, margins, composition, calcifications, and shape using the TIRADS (Thyroid Imaging Reporting and Data System) classification [21]. Fine-needle aspiration cytology (FNAC) remains the gold standard for definitive pre-operative diagnosis, with molecular marker testing (e.g., ThyroSeq, Afirma) improving diagnostic accuracy for indeterminate cytology [21].

Thyroid Malignancies

Differentiated thyroid cancer (DTC), comprising papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC), accounts for over 90% of all thyroid malignancies [22]. PTC, the most common form, frequently harbors BRAF V600E mutations, which activate the MAPK signaling pathway and are associated with aggressive clinicopathological features and radioiodine refractoriness [22]. FTC and Hurthle cell carcinoma present diagnostic challenges due to their follicular architecture and are distinguished from benign follicular adenoma only by evidence of capsular or vascular invasion [22].

Anaplastic thyroid cancer (ATC), though rare, is one of the most lethal human malignancies, with a median survival of 3-5 months from diagnosis [23]. Management of DTC involves thyroidectomy followed by risk-stratified RAI ablation and TSH-suppressive LT4 therapy [24]. Targeted therapies including sorafenib, lenvatinib, and BRAF/MEK inhibitors have demonstrated efficacy in radioiodine-refractory DTC and ATC, representing a paradigm shift toward molecularly guided treatment [22,23].

Nutritional Factors and Thyroid Health

Iodine is an indispensable micronutrient for thyroid hormone synthesis, and its deficiency remains the leading global cause of preventable brain damage and thyroid dysfunction [3]. Chronic iodine deficiency leads to hypothyroidism, goiter, cretinism, and impaired neurocognitive development [25]. Universal salt iodization programs have substantially reduced the global burden of iodine deficiency disorders; however, re-emergence has been reported in several European nations, highlighting the need for sustained public health interventions [25].

Emerging evidence implicates vitamin D deficiency in the pathogenesis of autoimmune thyroid diseases. Vitamin D receptors are expressed in thyroid tissue and immune cells, and vitamin D exerts immunomodulatory effects by promoting regulatory T cell differentiation and suppressing pro-inflammatory cytokines [26,27]. Cross-sectional studies have reported inverse associations between serum 25(OH)D levels and the prevalence of HT and GD, suggesting that vitamin D sufficiency may confer protection against thyroid autoimmunity [27]. Selenium, as an essential cofactor for deiodinase enzymes and glutathione peroxidase, also plays a pivotal role in thyroid hormone metabolism and antioxidant defense [14].

Diagnosis and Therapeutic Advances

Laboratory Diagnosis

Serum TSH, measured by third-generation immunometric assays with a functional sensitivity of 0.01-0.02 mIU/L, serves as the primary screening test for thyroid dysfunction due to its logarithmic inverse relationship with free T4 [28]. The reference range for TSH (typically 0.- 4.0 mIU/L) has been subject to ongoing debate, with some authorities advocating for a narrower upper limit based on data from thyroid-antibody-negative populations [29]. Free T4 and free T3 measurements complement TSH in assessing the degree of dysfunction, and thyroid autoantibody testing aids in establishing autoimmune etiology [10].

Pharmacological Management

Levothyroxine (LT4) monotherapy remains the standard of care for hypothyroidism, with dose individualization guided by serum TSH monitoring [15]. A subset of patients report persistent symptoms despite TSH normalization; in these cases, combination LT4/liothyronine (T3) therapy has been explored, with evidence suggesting benefit in patients harboring DIO2 gene polymorphisms [8]. For hyperthyroid conditions, ATDs, RAI, and surgery each offer distinct advantages and risk profiles, and treatment selection should be individualized [17].

Pregnancy necessitates careful thyroid management, as both overt and subclinical thyroid dysfunction are associated with adverse maternal and fetal outcomes, including miscarriage, preterm birth, preeclampsia, and impaired neurodevelopment [30]. Current Endocrine Society guidelines advocate trimester-specific TSH reference ranges and recommend universal screening or case-finding in high-risk pregnant women [30].

Conclusion

Thyroid disorders encompass a wide and clinically significant spectrum of pathologies that pose substantial individual and public health challenges. Advances in molecular biology, immunology, and diagnostic imaging have transformed our understanding of thyroid disease pathogenesis and enabled more precise, personalized therapeutic strategies. The elucidation of autoimmune mechanisms in Hashimoto's thyroiditis and Graves' disease, the development of molecular profiling in thyroid nodule evaluation, and the emergence of targeted oncologic therapies for radioiodine-refractory and anaplastic thyroid cancers represent milestones in the field. Nutritional determinants particularly iodine, selenium, and vitamin D continue to be recognized as modifiable risk factors warranting integration into preventive strategies. Future research priorities include the development of validated biomarkers for early disease detection, optimization of combination thyroid hormone replacement, and the translation of genomic discoveries into clinical practice. This review underscores the imperative for continued multidisciplinary investigation to advance thyroid health globally.

References

1. Brent GA. Mechanisms of thyroid hormone action. J Clin Invest. 2012; 122: 3035-3043.
2. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev. 2010; 31: 139-170.
3. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002; 87: 489-499.
4. Zimmermann MB. Iodine deficiency. Endocr Rev. 2009; 30: 376-408.
5. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003; 348: 2646-2655.
6. Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr Rev. 2003; 24: 694-717.

7. Larsen PR, Davies TF. Hypothyroidism and thyroiditis. In: Kronenberg HM, ed. Williams Textbook of Endocrinology. 11th ed. Philadelphia, PA: Saunders/Elsevier. 2008; 299-332.
8. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009; 94: 1623-1629.
9. Vanderpump MP. The epidemiology of thyroid disease. Br Med Bull. 2011; 99: 39-51.
10. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004; 291: 228-238.
11. Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012; 379: 1142-1154.
12. Rugge JB, Bougatsos C, Chou R. Screening and treatment of thyroid dysfunction: an evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015; 162: 35-45.
13. Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014; 13: 391-397.
14. Antonelli A, Ferrari SM, Corrado A, et al. Autoimmune thyroid disorders. Autoimmun Rev. 2015; 14: 174-180.
15. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014; 24: 1670-1751.
16. Smith TJ, Hegedüs L. Graves' disease. N Engl J Med. 2016; 375: 1552-1565.
17. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016; 26: 1343-1421.
18. Thyssen JP, Linneberg A, Menne T, et al. The epidemiology of contact allergy in the general population prevalence and main findings. Contact Dermatitis. 2007; 57: 287-299.
19. Vejbjerg P, Knudsen N, Perrild H, et al. The association between hypo-echogenicity or irregular echo pattern at thyroid ultrasonography and thyroid function in the general population. Eur J Endocrinol. 2006; 155: 547-552.
20. Moon WJ, Jung SL, Lee JH, et al. Benign and malignant thyroid nodules: US differentiation-multicenter retrospective study. Radiology. 2008; 247: 762-770.
21. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016; 26: 1-133.
22. Grani G, Lamartina L, Durante C, et al. Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. Lancet Diabetes Endocrinol. 2018; 6: 500-514.
23. Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012; 22: 1104-1139.
24. Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012; 367: 1663-1673.
25. Zimmermann MB, Jooste PL, Pandav CS. Iodine-deficiency disorders. Lancet. 2008; 372: 1251-1262.
26. Nettore IC, Albano L, Ungaro P, et al. Sunshine vitamin and thyroid. Rev Endocr Metab Disord. 2017; 18: 347-354.
27. Kim D. The role of vitamin D in thyroid diseases. Int J Mol Sci. 2017; 18: 1949.
28. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays. Clin Chem. 1996; 42: 140-145.
29. Wartofsky L, Dickey RA. The evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab. 2005; 90: 5483-5488.
30. De Groot LJ, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012; 97: 2543-2565.